SOUTH SAN FRANCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- Corgentech Inc. , a biotechnology company, today announced that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission. Upon being declared effective by the SEC, the shelf registration statement will permit the company, from time to time, to issue various securities for proceeds in the aggregate amount of up to $100 million. The terms of any such future offerings and the type of securities to be issued would be determined at the time of any future offering.
A shelf registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the shelf registration statement is declared effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Corgentech
Corgentech is a late-stage biopharmaceutical company which seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has four drug candidates in clinical development for multiple potential indications, the most advanced of which, 3268, has completed Phase 3 clinical trials. Corgentech is based in South San Francisco, CA.
Corgentech Inc.
CONTACT: Richard Powers, Chief Financial Officer of Corgentech Inc.,+1-650-624-9600, or investors@corgentech.com; Media, Daryl Messinger ofWeissComm Partners, +1-415-999-2361, or daryl@weisscommpartners.com, forCorgentech Inc.
Web site: http://www.corgentech.com//
